Pfizer’s Torcetrapib/Lipitor Raises HDL Cholesterol, But Blood Pressure Too
Executive Summary
Apparent increases in systolic blood pressure caused by Pfizer's torcetrapib/Lipitor (atorvastatin) combination will be investigated in further clinical studies, the firm said
You may also be interested in...
Merck Expects Expedited Filing Of HDL-Cholesterol Drugs Using Existing Data
Merck believes it will be able to submit its developmental atherosclerosis therapies targeting HDL cholesterol without conducting major outcomes trials, Merck Research Lab President Peter Kim said during the firm's annual business review in Whitehouse Station, N.J. Dec. 15
Merck Expects Expedited Filing Of HDL-Cholesterol Drugs Using Existing Data
Merck believes it will be able to submit its developmental atherosclerosis therapies targeting HDL cholesterol without conducting major outcomes trials, Merck Research Lab President Peter Kim said during the firm's annual business review in Whitehouse Station, N.J. Dec. 15
Pfizer Torcetrapib Phase III Program Will Cost $800 Mil.
Pfizer is spending $800 mil. on the Phase III development program for the cholesterol agent torcetrapib, Worldwide Development President Joe Feczko, MD, said during a Nov. 30 analysts meeting in Groton, Conn